The results showed a a 51% reduction in the rate of annual asthma exacerbations compared to albuterol. AstraZeneca’s Novel START trial for its Symbicort Turbuhaler ...

AstraZeneca PLC AZN announced positive results from a safety study on Symbicort inhaler in patients suffering from asthma compared to budesonide alone. Symbicort is presently marketed for the ...

The dosage for Symbicort may vary based on age and diagnosis, but it’s typically two inhalations twice daily. For children ages 6 to 11, the maximum strength is 80/4.5 mcg. For ages 12 and older, a ...

AstraZeneca PLCAZN announced positive results from a safety study on Symbicort inhaler in patients suffering from asthma compared to budesonide alone. Symbicort is presently marketed for the treatment ...

The US Food and Drug Administration has approved AstraZeneca's Symbicort inhalation aerosol (80/4.5 mcg) for children aged 6 to 12 years with asthma that is not well controlled with an inhaled ...

The pediatric approval was based on the results of the Phase 3 CHASE (ChildHood Asthma Safety and Efficacy) 3 trial. The Food and Drug Administration (FDA) has approved Symbicort (budesonide and ...

Symbicort, which is used to treat chronic obstructive pulmonary disease and asthma, can cause side effects. Mild side effects include nasal congestion and headaches. Serious side effects include ...